---
document_datetime: 2025-08-21 14:44:38
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/spevigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: spevigo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6830376
conversion_datetime: 2025-12-31 03:16:16.230946
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Spevigo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------|
| X/0011               | An extension application for a new strength of 300 mg (150 mg/ml) for solution for injection in a pre- filled syringe. The RMP (version 3.0) is updated in accordance. In addition, the applicant has updated SmPC (Annex I) and Package Leaflet (Annex IIIB) for both 450 mg | 19/06/2025                          | 14/08/2025                                  | SmPC, Labelling and PL           | Please refer to Scientific Discussion \"Spevigo EMEA/H/C/005874/X/0011\" |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | concentrate for solution for infusion and 150 mg and 300 mg solution for injection in line with the new excipient guideline Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                         |            |            |                                  |                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------|
| PSUSA/11033 /202409 | Periodic Safety Update EU Single assessment - spesolimab                                                                                                                                                                                                                                                                                                                                                       | 10/04/2025 | n/a        |                                  | PRAC Recommendation - maintenance                                        |
| R/0008              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                        | 19/09/2024 | 14/11/2024 |                                  |                                                                          |
| IB/0010             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                              | 05/11/2024 | n/a        |                                  |                                                                          |
| PSUSA/11033 /202403 | Periodic Safety Update EU Single assessment - spesolimab                                                                                                                                                                                                                                                                                                                                                       | 03/10/2024 | n/a        |                                  | PRAC Recommendation - maintenance                                        |
| X/0006/G            | This was an application for a group of variations. Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration (subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. This line extension is grouped with a type II variation | 25/07/2024 | 25/09/2024 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion \"Spevigo EMEA/H/C/005874/X/0006/G\" |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | (C.I.6.a) indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-center, randomised, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the PI and update the list of local representatives in the Package Leaflet. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration C.I.6.a - Change(s) to therapeutic indication(s) -   |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/11033 /202309 | Periodic Safety Update EU Single assessment - spesolimab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/04/2024 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| PSUSA/11033 /202303   | Periodic Safety Update EU Single assessment - spesolimab                                                                                                                                                                                                                                                                                                                                       | 28/09/2023   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| R/0005                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                        | 20/07/2023   | 15/09/2023 |                                     |
| IA/0004/G             | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 24/05/2023   | n/a        |                                     |
| IB/0002/G             | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                              | 23/05/2023   | n/a        |                                     |
| IB/0001               | B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                                                                                                                                                                                                                       | 28/02/2023   | n/a        |                                     |